GlassScriptPhysician profile
Wesley Wallis Walker
NPI 1134291727
$2,484.08
in general payments reported to CMS, 2019-2025
30 companies · $13.49 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $569 · 2021: $561 · 2022: $106 · 2023: $98.95 · 2024: $13.91 · 2025: $13.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $98.95 · Food and Beverage: $27.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $98.95 |
| Food and Beverage | $27.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $430.07 | 2019-2022 | |
| Daiichi Sankyo INC. | $265.05 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $239.47 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $234.70 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.48 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $113.46 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $95.49 | 2019-2022 | |
| Clovis Oncology, INC. | $95.11 | 2019-2020 | |
| Eisai INC. | $91.18 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $90.84 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $89.70 | 2019-2021 | |
| Lilly USA, LLC | $75.20 | 2019-2021 | |
| Glaxosmithkline, LLC. | $66.48 | 2020-2021 | |
| Seagen INC. | $62.18 | 2020-2022 | |
| Janssen Biotech, INC. | $56.23 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $42.78 | 2021 | |
| Abbvie INC. | $39.85 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.00 | 2019-2025 | |
| Tesaro, INC. | $33.12 | 2019 | |
| Incyte Corporation | $32.52 | 2020-2021 | |
| Coherus Oncology, INC. | $29.83 | 2020 | |
| Genzyme Corporation | $20.59 | 2020 | |
| Astellas Pharma US INC | $19.05 | 2020 | |
| Exelixis INC. | $16.82 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.65 | 2021 | |
| Myovant Sciences INC. | $15.00 | 2021 | |
| Portola Pharmaceuticals, LLC | $14.45 | 2019 | |
| Boston Scientific Corporation | $13.91 | 2024 | Spaceoar Vue System - 10ml |
| Pharmacyclics LLC, An Abbvie Company | $12.67 | 2020 | |
| Dova Pharmaceuticals | $12.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.